New Developments in Immunotherapy in Melanoma: Highlights from the 105th AACR Annual Meeting

Summary: <p>The American Association for Cancer Research (AACR) 105th Annual Meeting in San Diego invited discussion on the continued progress of immunotherapy for people with melanoma. This interview will review practice-changing data in melanoma, as presented at the AACR annual meeting. In particular, Dr. Flaherty will review the immune-stimulating effects of anti-ctla-4 and anti-pd-1 treatments that are evolving to improve the lives of people with melanoma.</p> <p>As of September 4, 2014, the FDA approved Pembrolizumab (Keytruda). This drug won FDA approval for treating advanced or unresectable melanoma in patients not responding to other therapies. This interview may include discussion on this drug or drugs in a related drug class. Please note this updated approval while participating in this activity. To learn more visit:<a href="http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm412802.htm"> http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm412802.htm</a><br><br></p> <p><img src="/media/images/cmsimages/CME/project_oncology_257.jpg" alt="" width="257" height="53" border="0"></p>